中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 40 Issue 6
Jun.  2024
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(6): 1275-1280

Role of T-cell immunoglobulin and mucin domain-containing molecule 3 in the development and progression of liver diseases

DOI: 10.12449/JCH240632

  • Department of Gastroenterology，The Second Affiliated Hospital of Kunming Medical University，Kunming 650101，China

Research funding:

National Natural Science Foundation of China (82360108);

Yunnan Medical Leading Talent Project (L-2019013);

Yunnan Ten Thousand Talents Project (YNWR-MY-2018-028);

China United Liver Health Promotion Center - Special Fund for Hepatitis E Prevention and Treatment (CLH2023-F-HEV-08);

Yunnan Provincial Science and Technology Talent and Platform Program (Academician Expert Workstation 202305AF150065);

Clinical Research Project of the Second Affiliated Hospital of Kunming Medical University (2020ynlc010);

Clinical Research Project of the Second Affiliated Hospital of Kunming Medical University (ynIIT2021017)

More Information
  • Corresponding author: TANG Yingmei， tangyingmei_med@kmmu.edu.cn （ORICID： 0000-0002-0731-4198）
  • Received Date: 2023-09-06
  • Accepted Date: 2023-10-10
  • Published Date: 2024-06-25
    Abstract
  • T-cell immunoglobulin and mucin domain-containing molecule-3 （Tim-3） is a member of the Tim family and has been a research hotspot in recent years. As a negative regulatory factor， Tim-3 exerts different effects by binding to different ligands. Tim-3 is expressed in various types of immune cells， such as natural killer cells， dendritic cells， and monocytes， and Tim-3 has a regulatory effect on the functions of these immune cells. In recent years， a large number of studies have shown that Tim-3 is closely associated with the development and progression of liver diseases. This article reviews the studies on the role and mechanism of Tim-3 in different liver diseases and cells in recent years， in order to provide richer perspectives and ideas for the clinical diagnosis and treatment of liver diseases.

     

    • FullText(HTML)
  • loading
    • References(47)
  • [1]
    CHENG L, RUAN ZH. Tim-3 and Tim-4 as the potential targets for antitumor therapy[J]. Hum Vaccin Immunother, 2015, 11( 10): 2458- 2462. DOI: 10.1080/21645515.2015.1056953.
    [2]
    KANDEL S, ADHIKARY P, LI GF, et al. The TIM3/Gal9 signaling pathway: An emerging target for cancer immunotherapy[J]. Cancer Lett, 2021, 510: 67- 78. DOI: 10.1016/j.canlet.2021.04.011.
    [3]
    SOLINAS C, de SILVA P, BRON D, et al. Significance of TIM3 expression in cancer: From biology to the clinic[J]. Semin Oncol, 2019, 46( 4-5): 372- 379. DOI: 10.1053/j.seminoncol.2019.08.005.
    [4]
    WU SS, DU XF, LOU GH, et al. Expression changes of Tim-3 as one of supplementary indicators for monitoring prognosis of liver pathological changes in chronic HBV infection[J]. BMC Infect Dis, 2022, 22( 1): 842. DOI: 10.1186/s12879-022-07841-1.
    [5]
    CLAYTON KL, DOUGLAS-VAIL MB, NUR-UR RAHMAN AK, et al. Soluble T cell immunoglobulin mucin domain 3 is shed from CD8+ T cells by the sheddase ADAM10, is increased in plasma during untreated HIV infection, and correlates with HIV disease progression[J]. J Virol, 2015, 89( 7): 3723- 3736. DOI: 10.1128/JVI.00006-15.
    [6]
    LAKE CM, VOSS K, BAUMAN BM, et al. TIM-3 drives temporal differences in restimulation-induced cell death sensitivity in effector CD8+ T cells in conjunction with CEACAM1[J]. Cell Death Dis, 2021, 12( 4): 400. DOI: 10.1038/s41419-021-03689-6.
    [7]
    VISHAL K, VIKAS D, PATIL AM, et al. CEACAM1 promotes CD8+T cell responses and improves control of a chronic viral infection[J]. Nature Communications, 2018, 9( 1): 2561. DOI: 10.1038/s41467-018-04832-2.
    [8]
    SORDI R, ÂC BET, DELLA JUSTINA AM, et al. The apoptosis clearance signal phosphatidylserine inhibits leukocyte migration and promotes inflammation resolution in vivo[J]. Eur J Pharmacol, 2020, 877: 173095. DOI: 10.1016/j.ejphar.2020.173095.
    [9]
    KANE LP. Regulation of Tim-3 function by binding to phosphatidylserine[J]. Biochem J, 2021, 478( 22): 3999- 4004. DOI: 10.1042/BCJ20210652.
    [10]
    WANG JY, LI C, FU JJ, et al. Tim-3 regulates inflammatory cytokine expression and Th17 cell response induced by monocytes from patients with chronic hepatitis B[J]. Scand J Immunol, 2019, 89( 5): e12755. DOI: 10.1111/sji.12755.
    [11]
    DAI SY, NAKAGAWA R, ITOH A, et al. Galectin-9 induces maturation of human monocyte-derived dendritic cells[J]. J Immunol, 2005, 175( 5): 2974- 2981. DOI: 10.4049/jimmunol.175.5.2974.
    [12]
    YU LH, LIU XL, WANG XH, et al. TIGIT+ TIM-3+ NK cells are correlated with NK cell exhaustion and disease progression in patients with hepatitis B virus-related hepatocellular carcinoma[J]. Oncoimmunology, 2021, 10( 1): 1942673. DOI: 10.1080/2162402X.2021.1942673.
    [13]
    LI F, FAN XD, WANG XY, et al. Genetic association and interaction of PD1 and TIM3 polymorphisms in susceptibility of chronic hepatitis B virus infection and hepatocarcinogenesis[J]. Discov Med, 2019, 27( 147): 79- 92.
    [14]
    MOHAMMADIZAD H, SHAHBAZI M, HASANJANI ROUSHAN MR, et al. TIM-3 as a marker of exhaustion in CD8+ T cells of active chronic hepatitis B patients[J]. Microb Pathog, 2019, 128: 323- 328. DOI: 10.1016/j.micpath.2019.01.026.
    [15]
    HOFMANN M, TAUBER C, HENSEL N, et al. CD8+ T cell responses during HCV infection and HCC[J]. J Clin Med, 2021, 10( 5): 991. DOI: 10.3390/jcm10050991.
    [16]
    LEE HM, BANINI BA. Updates on Chronic HBV: current challenges and future goals[J]. Curr Treat Options Gastroenterol, 2019, 17( 2): 271- 291. DOI: 10.1007/s11938-019-00236-3.
    [17]
    VIMALI J, YONG YK, MURUGESAN A, et al. Chronic viral infection compromises the quality of circulating mucosal-invariant T cells and follicular T helper cells via expression of both activating and inhibitory receptors[J]. Res Sq, 2023: rs. 3. rs-rs. 2862719. DOI: 10.21203/rs.3.rs-2862719/v1.
    [18]
    JIANG Y, LI Y, ZHU B. T-cell exhaustion in the tumor microenvironment[J]. Cell Death Dis, 2015, 6( 6): e1792. DOI: 10.1038/cddis.2015.162.
    [19]
    KOCHANOWICZ AM, OSUCH S, BERAK H, et al. Double positive CD4+CD8+(DP) T-cells display distinct exhaustion phenotype in chronic hepatitis C[J]. Cells, 2023, 12( 10): 1446. DOI: 10.3390/cells12101446.
    [20]
    WANG JM, SHI L, MA CJ, et al. Differential regulation of interleukin-12(IL-12)/IL-23 by Tim-3 drives T(H)17 cell development during hepatitis C virus infection[J]. J Virol, 2013, 87( 8): 4372- 4383. DOI: 10.1128/JVI.03376-12.
    [21]
    OKWOR CIA, OH JS, CRAWLEY AM, et al. Expression of inhibitory receptors on T and NK cells defines immunological phenotypes of HCV patients with advanced liver fibrosis[J]. iScience, 2020, 23( 9): 101513. DOI: 10.1016/j.isci.2020.101513.
    [22]
    MOTAMEDI M, SHAHBAZ S, FU L, et al. Galectin-9 expression defines a subpopulation of NK cells with impaired cytotoxic effector molecules but enhanced IFN-γ production, dichotomous to TIGIT, in HIV-1 infection[J]. ImmunoHorizons, 2019, 3( 11): 531- 546. DOI: 10.4049/immunohorizons.1900087.
    [23]
    FERRI S, LONGHI MS, de MOLO C, et al. A multifaceted imbalance of T cells with regulatory function characterizes type 1 autoimmune hepatitis[J]. Hepatology, 2010, 52( 3): 999- 1007. DOI: 10.1002/hep.23792.
    [24]
    MIGITA K, NAKAMURA M, AIBA Y, et al. Association of soluble T cell immunoglobulin domain and mucin-3(sTIM-3) and mac-2 binding protein glycosylation isomer(M2BPGi) in patients with autoimmune hepatitis[J]. PLoS One, 2020, 15( 12): e0238540. DOI: 10.1371/journal.pone.0238540.
    [25]
    WU HW, TANG SY, ZHOU MY, et al. Tim-3 suppresses autoimmune hepatitis via the p38/MKP-1 pathway in Th17 cells[J]. FEBS Open Bio, 2021, 11( 5): 1406- 1416. DOI: 10.1002/2211-5463.13148.
    [26]
    HYUN J, HAN J, LEE CB, et al. Pathophysiological aspects of alcohol metabolism in the liver[J]. Int J Mol Sci, 2021, 22( 11): 5717. DOI: 10.3390/ijms22115717.
    [27]
    RIVA A, PALMA E, DEVSHI D, et al. Soluble TIM3 and its ligands galectin-9 and CEACAM1 are in disequilibrium during alcohol-related liver disease and promote impairment of anti-bacterial immunity[J]. Front Physiol, 2021, 12: 632502. DOI: 10.3389/fphys.2021.632502.
    [28]
    POUWELS S, SAKRAN N, GRAHAM Y, et al. Non-alcoholic fatty liver disease(NAFLD): A review of pathophysiology, clinical management and effects of weight loss[J]. BMC Endocr Disord, 2022, 22( 1): 63. DOI: 10.1186/s12902-022-00980-1.
    [29]
    WANG CE, XU WT, GONG J, et al. Treatment of patients with nonalcoholic fatty liver disease[J]. Clin J Med Offic, 2022, 50( 9): 897- 899, 903. DOI: 10.16680/j.1671-3826.2022.09.06.

    王彩娥, 许文涛, 宫建, 等. 非酒精性脂肪性肝病治疗研究进展[J]. 临床军医杂志, 2022, 50( 9): 897- 899, 903. DOI: 10.16680/j.1671-3826.2022.09.06.
    [30]
    DU X, WU Z, XU Y, et al. Increased Tim-3 expression alleviates liver injury by regulating macrophage activation in MCD-induced NASH mice[J]. Cell Mol Immunol, 2019, 16( 11): 878- 886. DOI: 10.1038/s41423-018-0032-0.
    [31]
    KISSELEVA T, BRENNER D. Molecular and cellular mechanisms of liver fibrosis and its regression[J]. Nat Rev Gastroenterol Hepatol, 2021, 18( 3): 151- 166. DOI: 10.1038/s41575-020-00372-7.
    [32]
    BAILLY C. Contribution of the TIM-3/Gal-9 immune checkpoint to tropical parasitic diseases[J]. Acta Trop, 2023, 238: 106792. DOI: 10.1016/j.actatropica.2022.106792.
    [33]
    LIU X, LI C, ZHU J, et al. Dysregulation of FTX/miR-545 signaling pathway downregulates Tim-3 and is responsible for the abnormal activation of macrophage in cirrhosis[J]. J Cell Biochem, 2019, 120( 2): 2336- 2346. DOI: 10.1002/jcb.27562.
    [34]
    LIU SY, XU C, YANG F, et al. Natural killer cells induce CD8+ T cell dysfunction via galectin-9/TIM-3 in chronic hepatitis B virus infection[J]. Front Immunol, 2022, 13: 884290. DOI: 10.3389/fimmu.2022.884290.
    [35]
    HUANG N, ZHOU R, CHEN HY, et al. Splenic CD4+ and CD8+ T-cells highly expressed PD-1 and Tim-3 in cirrhotic patients with HCV infection and portal hypertension[J]. Int J Immunopathol Pharmacol, 2021, 35: 20587384211061051. DOI: 10.1177/20587384211061051.
    [36]
    FADRIQUELA A, KIM CS, LEE KJ, et al. Characteristics of immune checkpoint regulators and potential role of soluble TIM-3 and LAG-3 in male patients with alcohol-associated liver disease[J]. Alcohol, 2022, 98: 9- 17. DOI: 10.1016/j.alcohol.2021.10.002.
    [37]
    DAS M, ZHU C, KUCHROO VK. Tim-3 and its role in regulating anti-tumor immunity[J]. Immunol Rev, 2017, 276( 1): 97- 111. DOI: 10.1111/imr.12520.
    [38]
    GANJALIKHANI HAKEMI M, JAFARINIA M, AZIZI M, et al. The role of TIM-3 in hepatocellular carcinoma: A promising target for immunotherapy?[J]. Front Oncol, 2020, 10: 601661. DOI: 10.3389/fonc.2020.601661.
    [39]
    ZHAO L, JIN Y, YANG C, et al. HBV-specific CD8 T cells present higher TNF-α expression but lower cytotoxicity in hepatocellular carcinoma[J]. Clin Exp Immunol, 2020, 201( 3): 289- 296. DOI: 10.1111/cei.13470.
    [40]
    LIN ZW, JIANG CW, WANG PY, et al. Caveolin-mediated cytosolic delivery of spike nanoparticle enhances antitumor immunity of neoantigen vaccine for hepatocellular carcinoma[J]. Theranostics, 2023, 13( 12): 4166- 4181. DOI: 10.7150/thno.85843.
    [41]
    SONG CH, ZHANG J, WEN RC, et al. Improved anti-hepatocellular carcinoma effect by enhanced Co-delivery of Tim-3 siRNA and sorafenib via multiple pH triggered drug-eluting nanoparticles[J]. Mater Today Bio, 2022, 16: 100350. DOI: 10.1016/j.mtbio.2022.100350.
    [42]
    ZHAO QF, WANG YH, ZHAO BY, et al. Neoantigen immunotherapeutic-gel combined with TIM-3 blockade effectively restrains orthotopic hepatocellular carcinoma progression[J]. Nano Lett, 2022, 22( 5): 2048- 2058. DOI: 10.1021/acs.nanolett.1c04977.
    [43]
    XIE RP, GU MQ, ZHANG FB, et al. Current status and prospect of surgical technique of liver transplantation[J]. Organ Transplant, 2022, 13( 1): 105- 110. DOI: 10.3969/j.issn.1674-7445.2022.01.016

    谢闰鹏, 谷明旗, 张凤博, 等. 肝移植手术技术的现状和展望[J]. 器官移植, 2022, 13( 1): 105- 110. DOI: 10.3969/j.issn.1674-7445.2022.01.016.
    [44]
    QIN L, ZHENG WX, JIANG SM, et al. Noninvasive prediction of immune rejection after liver transplantation with T cell immunoglobulin domain, and mucin domain-3[J]. Transplant Proc, 2022, 54( 7): 1881- 1886. DOI: 10.1016/j.transproceed.2022.04.032.
    [45]
    KOJIMA H, KADONO K, HIRAO H, et al. T cell CEACAM1-TIM-3 crosstalk alleviates liver transplant injury in mice and humans[J]. Gastroenterology, 2023, 165( 5): 1233- 1248. e 9. DOI: 10.1053/j.gastro.2023.07.004
    [46]
    RIFF A, HAEM RAHIMI M, DELIGNETTE MC, et al. Assessment of neutrophil subsets and immune checkpoint inhibitor expressions on T lymphocytes in liver transplantation: A preliminary study beyond the neutrophil-lymphocyte ratio[J]. Front Physiol, 2023, 14: 1095723. DOI: 10.3389/fphys.2023.1095723
    [47]
    MYSORE KR, GHOBRIAL RM, KANNANGANAT S, et al. Longitudinal assessment of T cell inhibitory receptors in liver transplant recipients and their association with posttransplant infections[J]. American Journal of Transplantation, 2018. DOI: 10.1111/ajt.14546.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (293) PDF downloads(31) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return